178 related articles for article (PubMed ID: 25456387)
1. Design, synthesis and biological evaluation of FLT3 covalent inhibitors with a resorcylic acid core.
Xu J; Ong EHQ; Hill J; Chen A; Chai CLL
Bioorg Med Chem; 2014 Dec; 22(23):6625-6637. PubMed ID: 25456387
[TBL] [Abstract][Full Text] [Related]
2. Discovery and development of extreme selective inhibitors of the ITD and D835Y mutant FLT3 kinases.
Baska F; Sipos A; Őrfi Z; Nemes Z; Dobos J; Szántai-Kis C; Szabó E; Szénási G; Dézsi L; Hamar P; Cserepes MT; Tóvári J; Garamvölgyi R; Krekó M; Őrfi L
Eur J Med Chem; 2019 Dec; 184():111710. PubMed ID: 31614258
[TBL] [Abstract][Full Text] [Related]
3. Identification of a potent 5-phenyl-thiazol-2-ylamine-based inhibitor of FLT3 with activity against drug resistance-conferring point mutations.
Chen CT; Hsu JT; Lin WH; Lu CT; Yen SC; Hsu T; Huang YL; Song JS; Chen CH; Chou LH; Yen KJ; Chen CP; Kuo PC; Huang CL; Liu HE; Chao YS; Yeh TK; Jiaang WT
Eur J Med Chem; 2015 Jul; 100():151-61. PubMed ID: 26081023
[TBL] [Abstract][Full Text] [Related]
4. A series of novel aryl-methanone derivatives as inhibitors of FMS-like tyrosine kinase 3 (FLT3) in FLT3-ITD-positive acute myeloid leukemia.
Sellmer A; Pilsl B; Beyer M; Pongratz H; Wirth L; Elz S; Dove S; Henninger SJ; Spiekermann K; Polzer H; Klaeger S; Kuster B; Böhmer FD; Fiebig HH; Krämer OH; Mahboobi S
Eur J Med Chem; 2020 May; 193():112232. PubMed ID: 32199135
[TBL] [Abstract][Full Text] [Related]
5. Facile identification of dual FLT3-Aurora A inhibitors: a computer-guided drug design approach.
Chang Hsu Y; Ke YY; Shiao HY; Lee CC; Lin WH; Chen CH; Yen KJ; Hsu JT; Chang C; Hsieh HP
ChemMedChem; 2014 May; 9(5):953-61. PubMed ID: 24665000
[TBL] [Abstract][Full Text] [Related]
6. Discovery of the selective and efficacious inhibitors of FLT3 mutations.
Zhi Y; Li B; Yao C; Li H; Chen P; Bao J; Qin T; Wang Y; Lu T; Lu S
Eur J Med Chem; 2018 Jul; 155():303-315. PubMed ID: 29894944
[TBL] [Abstract][Full Text] [Related]
7. Discovery and rational design of 2-aminopyrimidine-based derivatives targeting Janus kinase 2 (JAK2) and FMS-like tyrosine kinase 3 (FLT3).
Li Y; Wang P; Chen C; Ye T; Han Y; Hou Y; Liu Y; Gong P; Qin M; Zhao Y
Bioorg Chem; 2020 Nov; 104():104361. PubMed ID: 33142418
[TBL] [Abstract][Full Text] [Related]
8. Synthesis and biological evaluation of novel thieno[2,3-d]pyrimidine-based FLT3 inhibitors as anti-leukemic agents.
Yang JS; Park CH; Lee C; Kim H; Oh C; Choi Y; Kang JS; Yun J; Jeong JH; Kim MH; Han G
Eur J Med Chem; 2014 Oct; 85():399-407. PubMed ID: 25108079
[TBL] [Abstract][Full Text] [Related]
9. Discovery and evaluation of 3-phenyl-1H-5-pyrazolylamine-based derivatives as potent, selective and efficacious inhibitors of FMS-like tyrosine kinase-3 (FLT3).
Lin WH; Hsieh SY; Yen SC; Chen CT; Yeh TK; Hsu T; Lu CT; Chen CP; Chen CW; Chou LH; Huang YL; Cheng AH; Chang YI; Tseng YJ; Yen KR; Chao YS; Hsu JT; Jiaang WT
Bioorg Med Chem; 2011 Jul; 19(14):4173-82. PubMed ID: 21708468
[TBL] [Abstract][Full Text] [Related]
10. Synthesis and characterization of amino acid substituted sunitinib analogues for the treatment of AML.
Nemes Z; Takács-Novák K; Völgyi G; Valko K; Béni S; Horváth Z; Szokol B; Breza N; Dobos J; Szántai-Kis C; Illyés E; Boros S; Kok RJ; Őrfi L
Bioorg Med Chem Lett; 2018 Aug; 28(14):2391-2398. PubMed ID: 29935772
[TBL] [Abstract][Full Text] [Related]
11. Rational design of resorcylic acid lactone analogues as covalent MNK1/2 kinase inhibitors by tuning the reactivity of an enamide Michael acceptor.
Xu J; Chen A; Joy J; Xavier VJ; Ong EH; Hill J; Chai CL
ChemMedChem; 2013 Sep; 8(9):1483-94. PubMed ID: 23929665
[TBL] [Abstract][Full Text] [Related]
12. Synthesis and biological evaluation of 4-(4-aminophenyl)-6-methylisoxazolo[3,4-b] pyridin-3-amine covalent inhibitors as potential agents for the treatment of acute myeloid leukemia.
Kang JB; Chen L; Leng XJ; Wang JJ; Cheng Y; Wu SH; Ma YY; Yang LJ; Cao YH; Yang X; Tong ZJ; Wu JZ; Wang YB; Zhou H; Liu JC; Ding N; Dai WC; Yu YC; Xue X; Sun SL; Dai XB; Chang L; Wang XL; Li NG; Shi ZH
Bioorg Med Chem; 2022 Sep; 70():116937. PubMed ID: 35863236
[TBL] [Abstract][Full Text] [Related]
13. Synthesis and biological evaluation of diaryl urea derivatives as FLT3 inhibitors.
Zhang Q; Zhao K; Zhang L; Jiao X; Zhang Y; Tang C
Bioorg Med Chem Lett; 2020 Dec; 30(23):127525. PubMed ID: 32898697
[TBL] [Abstract][Full Text] [Related]
14. Novel acylureidoindolin-2-one derivatives as dual Aurora B/FLT3 inhibitors for the treatment of acute myeloid leukemia.
Jagtap AD; Chang PT; Liu JR; Wang HC; Kondekar NB; Shen LJ; Tseng HW; Chen GS; Chern JW
Eur J Med Chem; 2014 Oct; 85():268-88. PubMed ID: 25089810
[TBL] [Abstract][Full Text] [Related]
15. FMS-like tyrosine kinase 3 (FLT3) inhibitors: Molecular docking and experimental studies.
Mashkani B; Tanipour MH; Saadatmandzadeh M; Ashman LK; Griffith R
Eur J Pharmacol; 2016 Apr; 776():156-66. PubMed ID: 26896780
[TBL] [Abstract][Full Text] [Related]
16. Cis-enone resorcylic acid lactones (RALs) as irreversible protein kinase inhibitors.
Wei L; Wu J; Li G; Shi N
Curr Pharm Des; 2012; 18(9):1186-98. PubMed ID: 22316158
[TBL] [Abstract][Full Text] [Related]
17. Discovery of a potent Gilteritinib-based FLT3-PROTAC degrader for the treatment of Acute myeloid leukemia.
Ye L; Cui Z; Sun Y; Zhou H; Rong Q; Wang D; Jin J; Zhang Q; Kang D; Hu L; Wang J
Bioorg Chem; 2024 Aug; 149():107477. PubMed ID: 38820938
[TBL] [Abstract][Full Text] [Related]
18. Discovery of 3-phenyl-1H-5-pyrazolylamine derivatives containing a urea pharmacophore as potent and efficacious inhibitors of FMS-like tyrosine kinase-3 (FLT3).
Lin WH; Hsu JT; Hsieh SY; Chen CT; Song JS; Yen SC; Hsu T; Lu CT; Chen CH; Chou LH; Yang YN; Chiu CH; Chen CP; Tseng YJ; Yen KJ; Yeh CF; Chao YS; Yeh TK; Jiaang WT
Bioorg Med Chem; 2013 Jun; 21(11):2856-67. PubMed ID: 23618709
[TBL] [Abstract][Full Text] [Related]
19. Design, synthesis and biological evaluation of indolin-2-one-based derivatives as potent, selective and efficacious inhibitors of FMS-like tyrosine kinase3 (FLT3).
Ma F; Liu P; Lei M; Liu J; Wang H; Zhao S; Hu L
Eur J Med Chem; 2017 Feb; 127():72-86. PubMed ID: 28038328
[TBL] [Abstract][Full Text] [Related]
20. The antitumor compound triazoloacridinone C-1305 inhibits FLT3 kinase activity and potentiates apoptosis in mutant FLT3-ITD leukemia cells.
Augustin E; Skwarska A; Weryszko A; Pelikant I; Sankowska E; Borowa-Mazgaj B
Acta Pharmacol Sin; 2015 Mar; 36(3):385-99. PubMed ID: 25640477
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
